Tonix Pharmaceuticals Holding Corp.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Tonix Pharmaceuticals Holding Corp.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Shareholder Slice Ratio: Share count rose 334,404% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than almost all Healthcare companies in United States.
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 98% of Healthcare companies in United States.
- Tangible Net Worth Ratio: Of every $100 of net worth, $100 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 97% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-23.1×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 60% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
3/3 · 1/3Sales grew in 3 of the last 3 years; profit grew in 1 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-798.8×Operating cash was negative last year, while some debt falls due within a year.
Lower than 98% of Healthcare companies in United States.
Cash Cushion Ratio
2.3× cashCash, after subtracting all debt, is 2.3 times its market value (net cash).
Higher than 96% of Healthcare companies in United States.
Tangible Assets Ratio
100%Of every $100 the company owns, $100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 96% of Healthcare companies in United States.
Tangible Net Worth Ratio
100%Of every $100 of net worth, $100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 97% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Tonix Pharmaceuticals Holding Corp. made a loss over the last year. Tonix Pharmaceuticals Holding Corp. owes $0.13 for every $1 it owns. Tonix Pharmaceuticals Holding Corp. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossTonix Pharmaceuticals Holding Corp. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.40The share price is 0.40 times Tonix Pharmaceuticals Holding Corp.'s book value per share, lower than 94% of Healthcare companies in United States.
Market cap
$88 MThe total market value of all of Tonix Pharmaceuticals Holding Corp.'s shares at today's price (share price × number of shares), smaller than 67% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$222 MWhat Tonix Pharmaceuticals Holding Corp. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$12.96Net worth divided by the number of shares. The share price of $5.13 is 0.4 times this, which is the P/B above.
Return on equity (ROE)
-81.8%Tonix Pharmaceuticals Holding Corp. lost 81.8% of its shareholders' money over the last year, lower than 66% of Healthcare companies in United States.
Owes vs Owns
0.13×Tonix Pharmaceuticals Holding Corp. owes $0.13 for every $1 it owns (low), lower than 83% of Healthcare companies in United States.
Dividend yield
NoneTonix Pharmaceuticals Holding Corp. does not currently pay a dividend.
Revenue growth
+30%Revenue rose 30% in the year to Dec 2025.
Profit growth
LossTonix Pharmaceuticals Holding Corp. made a loss in each of the last two years.
Profit margin
-946.2%Tonix Pharmaceuticals Holding Corp. lost $946 for every $100 of revenue.
Interest cover
Not coveredTonix Pharmaceuticals Holding Corp.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashTonix Pharmaceuticals Holding Corp. held $206 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Tonix Pharmaceuticals Holding Corp.: $88 M ÷ $222 M (30 Jun 2026) = 0.4.
What is Tonix Pharmaceuticals Holding Corp.'s return on equity?
Tonix Pharmaceuticals Holding Corp. lost 81.8% of its shareholders' money over the last year, lower than 66% of Healthcare companies in United States.
How much does Tonix Pharmaceuticals Holding Corp. owe compared with what it owns?
Tonix Pharmaceuticals Holding Corp. owes $0.13 for every $1 it owns (low), lower than 83% of Healthcare companies in United States.
Does Tonix Pharmaceuticals Holding Corp. pay a dividend?
No. Tonix Pharmaceuticals Holding Corp. does not currently pay a dividend.
Is Tonix Pharmaceuticals Holding Corp.'s revenue growing?
Revenue rose 30% in the year to Dec 2025.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.